United Therapeutics spent more than a year consolidating around its 2015 highs. Now the biotech may be attempting a breakout.
Notice the surge to new all-time highs late last month. The rally followed news that the Food & Drug Administration approved its Tyvaso DPI hypertension drug for two applications. (There were worries of a narrower approval.)
UTHR paused for about three weeks and pulled back toward $215. That level is …
For more, please click here to view the related idea and chart analysis on TradingView.
